share_log

微芯生物(688321.SH):西奥罗尼胶囊治疗胰腺癌获得药物临床试验批准通知书

Shenzhen Chipscreen Biosciences (688321.SH): Xioroni capsules for the treatment of pancreatic cancer have obtained the drug clinical trial approval notice.

Gelonghui Finance ·  Jun 17 05:39

Chipscreen Biosciences (688321.SH) announced on June 17th that the company and its wholly-owned subsidiary, Chengdu Chipscreen Pharmaceutical Co., Ltd., has recently received the approval notice for domestic production of pharmaceutical clinical trial registration issued by the National Medical Products Administration. The application for phase II clinical trial of Xioloron combined with albumin-bound paclitaxel and gemcitabine for first-line treatment of advanced pancreatic cancer has been approved.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment